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Abstract 1	
Aside its historical use in contact with bone and teeth, an increasing number of studies use bioactive 2	
glasses (BG) in contact with soft tissue. BG could provide solutions for various medical problems. 3	
This study presents a first evaluation, whether BG containing silicone elastomers are a suitable 4	
material for left ventricular assist device drivelines and could enhance skin biointegration thereof. 5	
Three different nano- or microparticles of BG45S5® were incorporated into medical grade silicone 6	
elastomer and thin films of the composites were manufactured. Physicochemical, mechanical and in 7	
vitro experiments using primary human dermal fibroblasts were used to evaluate the nano- and 8	
microcomposites. The incorporation of BG particles reduced the tensile strength at break and percent 9	
elongation at break of the composites and increased the stiffness of the material. Especially the 10	
incorporation of nanosized BG decreased the percent elongation at break after immersion in SBF due 11	
to agglomerate formation and increased hydroxyapatite formation compared to commercially available 12	
microparticles. The cytocompatibility of BG containing composites increased significantly with 13	
increasing particle concentration. A clear trend regarding particle size was not observed. In general, 14	
the simple incorporation of particles into medical grade silicone elastomer allowed an easy 15	
modification of the mechanical properties and improvement in bioactivity (assessed by hydroxyapatite 16	
formation) of the material. The choice of either nano- or microparticles depends on the specific 17	
application and requirements for the material, as different particle types show different advantages and 18	
disadvantages.  19	
 20	
Keywords: Bioactive glass; Human primary dermal fibroblasts; Nanoparticles; Silicone composite; 21	
Percutaneous device   22	
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1 Introduction 1	
Bioactive glass (BG) is an amorphous material, which consists of a combination of various oxides. Its 2	
classical and best known composition is BG 45S5®, described by Hench et al. in 1971 with a 3	
composition of 45 wt.% SiO2, 24.5 wt.% Na2O, 24.5 wt.% CaO and 6 wt.% P2O5 [1-3]. Its properties 4	
such as bioactivity, osteoconductivity and osteostimulation make BG a suitable material in contact 5	
with hard tissue such as bone and teeth [4]. The bioactive properties of BG result from its reaction 6	
with the body fluids to form a direct bond with bone [1,2]. Also, its leaching in body fluids causes a 7	
change in the local ionic environment, which stimulates osteoblast proliferation, increases 8	
angiogenesis and acts antibacterial [5-10].  9	
Besides the use of BG with hard tissue, an increasing number of studies used BG in contact with soft 10	
tissue. Miguez-Pacheco et al. (2015) have presented a thorough literature review on this topic [8]. 11	
They reported multiple studies, which showed that “BG can have a stimulatory effect on angiogenesis, 12	
which is also applicable to soft tissue engineering” [8]. The applicability of BG for cardiac tissue 13	
engineering, wound healing and dressing, nerve regeneration, gastrointestinal regeneration, urinary 14	
tract and lung tissue engineering, laryngeal repair and stabilization of percutaneous devices is also 15	
reported [11-22].  16	
The combination of the aforementioned and well-known properties of BG and the recently reported 17	
findings could provide further possible solutions for other medical problems. Issues are e.g. faced in 18	
heart surgery and in more detail in heart replacement therapy. An increasing number of left ventricular 19	
assist devices (LVADs) are implanted into patients with heart failure every year, reaching 5’000 20	
devices in 2015 [23]. LVADs are small blood pumps, which are implanted into the body and support 21	
the weakened heart. These implants are either driven electrically or pneumatically, which requires a 22	
percutaneous lead, the so called driveline, which connects the power source with the implanted LVAD 23	
in the body. The situation is sketched in Fig. 1. The driveline exit site (DLES) is the place, where the 24	
lead exits the patient and is considered as the “Achilles heel” of LVADs [23]. It is most susceptible to 25	
infection and constitutes as an entry point for germs [24]. In one of the trials for the HeartMate II, a 26	
currently frequently implanted LVAD, an infection rate of 37% per patient-year was reported [23,25].  27	
 28	
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The LVAD drivelines are approximately 95 cm long and partly covered with a polyethylene 1	
terephthalate or polyester velour (Dacron® velour) with a length of approximately 30 cm [26]. The 2	
velour is used, because it offers reasonable epidermal biointegration [27]. In the past, the velour was 3	
placed at the driveline exit site, with an externalized part of approximately 2 cm (Fig. 1a), because it 4	
was believed to promote tissue ingrowth and thus, optimize the driveline stability at the driveline exit 5	
site [24,26]. However, cardiac surgeons started to put the smooth silicone or polyurethane surface of 6	
the leads itself at the position of the driveline exit site due to seemingly reduced infection rates and 7	
faster skin incorporation, thus internalizing the entire velour-covered portion of the driveline (Fig. 1b) 8	
[23,28,29]. The reason for these better patient outcomes are believed to be less dermal inflammation of 9	
the polymer-skin interface, compared to a velour-skin interface, thus yielding faster incorporation of 10	
the skin [30]. However, infections still occur very frequently [24]. The main reason for infections with 11	
a polymer-skin interface is believed to be trauma at the driveline exit site, disrupting the integrity of 12	
the driveline-skin barrier and thus, giving an entry point for germs [24]. Therefore, a long term stable 13	
connection of skin with the driveline’s material, e.g. silicone, giving mechanical stability between the 14	
polymer and skin, is desirable.  15	
Ross et al. (2003) tackled a similar problem. They used microscale particles of BG45S5® to coat a 16	
peritoneal dialysis catheter, and studied its influence on tissue ingrowth by implanting the coated 17	
silicone catheters subcutaneously in a rat model [20,21]. They showed that the BG coated tubes were 18	
“palpably fixed to the soft tissue”, while the uncoated control did not result in a stable tissue-silicone 19	
interface [21]. This concept of using bioactive glass on the surface of percutaneous devices could also 20	
be applied to percutaneously implanted drivelines of LVADs, in order to allow a faster formation and 21	
more stable polymer-skin interface, thus giving improved mechanical stability and a long-term stable 22	
barrier against pathogens.  23	
To study the influence of BG45S5® particles on silicone elastomers, different BG particles were 24	
incorporated into medical grade silicone. It is of significant interest, whether the incorporation of these 25	
bioactive particles into the silicone elastomer influence their mechanical properties. Further in vitro 26	
tests using simulated body fluid and cell culture tests with human primary dermal fibroblasts were 27	
used for a first assessment, whether the material could be suitable for skin biointegration. We therefore 28	
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investigated, whether the incorporation of different BG45S5® particles in medical grade silicone 1	
elastomers improves the mechanical properties, the bioactivity and cytocompatibility of silicone 2	
elastomers. These experiments provide a first approximation, if BG containing silicone could be used, 3	
and if it could improve the polymer-skin interface of percutaneous devices, especially at the driveline 4	
exit site of LVAD drivelines.   5	
6	
	
2 Materials and Methods 1	
2.1 Production of the bioactive glass containing films 2	
Nanoscale bioactive glass particles (nano-BG) of the type 45S5® were produced using flame spray 3	
synthesis as described earlier by Brunner et al. (2006) [31]. Briefly, the corresponding amounts of 4	
precursors (based on Si, Na, Ca and P) were mixed and diluted with tetrahydrofuran (THF, inhibitor-5	
free, Sigma-Aldrich, Buchs, Switzerland) at a volumetric ratio of 2:1. The mixture was dispersed in 6	
oxygen and ignited in a methane and oxygen flame. The nanoparticles were collected on a filter and 7	
sieved subsequently. The commercially available microscale particles were provided by Schott 8	
(Schott-BG, bioactive glass 45S5®, SCHOTT, Landshut, Germany) and mo-Science (Mo-Sci-BG, 9	
45S5® Bioactive Powder, Mo-Sci Health Care LLC, Rolla MO, United States). Schott-BG has a 10	
primary particle size of 4 µm and Mo-Sci-BG has a primary particle size of ≤ 54 µm, as specified by 11	
the suppliers. The silicone elastomer films with the specific BG content (Table 1) were produced by 12	
blending particles into a 2-component addition cure medical grade silicone elastomer (silicone, 13	
Silicone Elastomer A-103, Factor II Inc., Lakeside AZ, United States), which is cured by a platinum 14	
catalyst. According to the supplier, the platinum catalyst was included in component A. In detail, the 15	
corresponding amounts of silicone component A and BG particles were mixed in a dual-axis 16	
centrifuge (Speed Mixer DAC 150 FVZ, Hausschild Engineering, Hamm, Germany) for 2 minutes at 17	
3500 rounds per minute (rpm). Afterwards, vacuum was applied to 8 mbar for approximately 5 18	
minutes. For each sample this procedure was repeated 4 times. Afterwards, the corresponding amount 19	
of silicone component B was added and again mixed for 2 minutes at 3500 rpm. The uncured BG-20	
silicone mixture was degassed to 8 mbar for approximately 10 minutes. The films were prepared using 21	
an automatic film applicator (Elcometer 4340, 120 µm rakle, Elcometer Instruments GmbH, Germany) 22	
on aluminium sheets, which had been washed with ethanol (EtOH, puriss. p.a., Sigma Aldrich) before. 23	
Subsequently, the films were cured at 150 °C in an oven for 6 hours.   24	
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Table 1. Silicone composites with different bioactive glass (BG) loadings and types 1	
Particle type  
Primary particle diameter [µm]1 
control 
 
nano-BG 
0.02 – 0.06 
Schott-BG 
4 
Mo-Sci-BG 
≤ 54 
Concentrations 0 wt.% 5 wt.%  
10 wt.% 
2 
5 wt.% 
10 wt.% 
15 wt.% 
5 wt.% 
10 wt.% 
15 wt.% 
1as specified by supplier or literature [31]; 215 wt.% nano-BG could not be manufactured; 2	
 3	
2.2 Characterization of the materials 4	
2.2.1 Characterization of Bioglass 45S5® particles 5	
BG45S5® particles were analysed by scanning electron microscopy (SEM, FEI NovaNanoSEM450, 6	
FEI, Eindhoven, The Netherlands). Prior to SEM, the samples were sputtered with a 5 nm layer of 7	
platinum. The particle size distribution (PSD) was measured by analysing the size of at least 300 8	
particles in a random area for each sample. The diameter of the particles was determined using an 9	
ellipse to fit the particles’ outlines and taking the average of the major axis and the minor axis as the 10	
approximate diameter of each particle.  11	
 12	
2.2.2 In vitro tests using simulated body fluid and analysis of bioactive glass containing films 13	
The in vitro bioactivity of BG containing films was tested in simulated body fluid (SBF). SBF was 14	
prepared according to Kokubo and Takadama with a pH of 7.4 [32]. Films were cut (100 x 20 mm) 15	
and washed in ethanol, dried in vacuum overnight and weighed (M0, dry). Afterwards, each sample was 16	
incubated in 45 mL of freshly prepared SBF in a water bath at 36.5 °C for 4 weeks and SBF was 17	
replaced once a week. After incubation, the samples were gently dried on paper, weighed (Mt, wet) and 18	
afterwards dried in vacuum for 1 week. Dried samples were weighed (Mt, dry) to determine the weight 19	
loss (%WL) and water uptake (%WA) [33], which were calculated according to  20	
 21	
%𝑊𝐿 = 𝑀!,!"# −𝑀!,!"#𝑀!,!"#  ×100 
8	
	
%𝑊𝐴 = 𝑀!,!"# −𝑀!,!"#𝑀!,!"#  ×100. 
 1	
The formation of hydroxyapatite (HAp) of the samples was analysed by taking SEM images of the 2	
planar section as well as the cross-section of all samples before and after immersion in SBF. The 3	
samples for the cross-sectional SEM images were frozen using liquid nitrogen (LN2). Two tweezers, 4	
whose tips had also been cooled in LN2, were used to break the film and form a break line. The films 5	
were mounted on the SEM sample holders and sputtered as described earlier. Cross-sectional SEM 6	
images were taken of this break line.  Additionally, X-ray diffraction (XRD, X’Pert PRO-MPD, 7	
PANalytical, Almelo, The Netherlands) was used with Ni-filtered Cu Kα radiation (λ = 0.1541 nm) 8	
from 10-70° in the 2Θ scale with a step size of 0.05° at 6 s per step to confirm the presence of HAp.  9	
 10	
2.3 Physical properties analysis 11	
ASTM test method D882 – 12 was used to measure the influence of the different particles and 12	
concentrations on the mechanical properties of the silicone. Briefly, BG-silicone composite films were 13	
cut into rectangles (100 x 20 mm) and the thickness of the films was measured (Digimatic Outside 14	
Micrometer IP65, Mitutoyo, Urdorf, Switzerland) at 3 random locations on each sample to ensure a 15	
variation in thickness of less than 10%. The mechanical properties were tested of as-prepared BG-16	
silicone films (n ≥  4) and BG-silicone films, which had been immersed in SBF for 4 weeks (n ≥  3) 17	
using a tensile tester (Shimadzu AGS-X, 10 kN load cell, Reinach, Switzerland). The gauge length 18	
was 50 mm and the test speed was 500 mm min-1.  Engineering stress and engineering strain were 19	
measured and a tangent in the linear regime of the stress-strain curve was used to calculate the 20	
Young’s modulus. Measurements were conducted until failure of the material and measurements of 21	
rupture at the grip were not considered. Static contact angle measurements (NRL C, Ramé-hart Inc., 22	
Randolph NJ, United States) were performed in order to determine the hydrophobicity of the as-23	
prepared samples. 20 µL drops of deionized water were added on the surface. Every sample was 24	
analysed using three droplets. The left angle of each droplet was measured for 36 s at a rate of 25 25	
images per second, which gave 901 measurements of the static contact angle. The average of these 26	
9	
	
measurements was used to give the static contact angle of each droplet, while the average of the three 1	
droplets gave the reported value of each material. 2	
 3	
2.4 Cell culture study 4	
2.4.1 Materials 5	
Normal Human Primary Dermal Fibroblasts from neonatal foreskin were purchased from ATCC 6	
(ATCC® PCS-201-010TM, Manassas VA, United States). The cells were cultivated in Fibroblast Basal 7	
Medium (FBM, Lonza, Walkersville MD, United States) using a low serum Fibroblast Growth 8	
Medium Kit (FGM-2 SingleQuot Kit Suppl. & Growth Factors, Lonza) and incubated at 37 °C in 9	
humidified air (37 °C, 5% CO2). Dulbecco’s Phosphate Buffered Saline (DPBS (1X), gibco®, Paisley, 10	
United Kingdom) was applied to wash the cells, while Trypsin-EDTA (0.25% Trypsin-EDTA (1X), 11	
gibco®) was used for trypsinisation of the cells.  12	
 13	
2.4.2 Test samples and cell seeding 14	
Uncured BG-silicone was filled into 48 well plates (Nunclon Delta Surface 48 well plate, Thermo 15	
Fischer Scientific, Waltham MA, United States), shaken orbital by hand and cured in an oven at 40 °C 16	
for 7 days. Afterwards, the cell culture plates were disinfected with UV-C light from four low pressure 17	
mercury lamps (253.7 nm, 15 W, HNS 15 ORF, Osram). The UV-C lamps were set at a distance of 18	
50 cm from the sample, resulting in a dose rate of approximately 5.2 W m-2. The irradiation output was 19	
measured by a standard photodiode sensor (PD300-UV, 200-1100 nm, 3 mW 20 pW, OphirPhotonics) 20	
[34]. Cells (passage #5) were seeded at a concentration of 2,500 cells cm-2 in 600 µL FBM and 21	
incubated at 37 °C and 5% CO2 for up to 7 days. For every material 12 wells were sampled, 4 for 22	
every measuring time. The medium was changed every 48 hours.  23	
 24	
2.4.3 Relative cell proliferation assay 25	
Relative cell proliferation of human primary dermal fibroblasts on the different materials was 26	
measured using a commercial cell viability reagent (PrestoBlueTM Cell Viability Reagent, Invitrogen 27	
Ltd., Paisley, United Kingdom), which assesses the cell viability via the metabolic activity of the cells. 28	
10	
	
The reagent was first filtered (Filtropur S 0.2, Sarstedt AG & Co., Nürnbrecht, Germany). 60 µL of the 1	
filtered viability reagent were added to each well containing the different materials. For each 2	
measuring time, 4 replicates of every composite were assessed. After addition of the viability reagent, 3	
the well plate was gently shaken and incubated at 37 °C in humidified air for 2 hours. Three times 4	
100 µL of each sampled well were added to a 96-well plate (Tissue Culture Test Plate 96F, TPP®, 5	
Trasadingen, Switzerland) and analysed using fluorescence (TECAN infinite F200, Tecan Group Ltd., 6	
Männedorf, Switzerland) at an absorbance of 560 nm and emission of 590 nm at 4 different spots in 7	
every well. The cell proliferation assay was conducted 1 day, 3 days and 7 days after cell seeding. 8	
 9	
2.5 Statistical analysis 10	
Results are represented as mean ± standard deviation. The number of samples differed, but was noted, 11	
at the presentation of the results, when useful. Statistical significance was analysed using one-way 12	
analysis of variance (ANOVA) with a Bonferroni’s post-hoc correction (OriginPro 9.1.0, Origin Lab 13	
Corp. Northampton MA, United States). Significance of the results of the experiments was assumed at 14	
a p value of < 0.05.   15	
11	
	
3 Results 1	
3.1 Bioactive glass characterization 2	
The three particle types differed in their shape and primary particle size (Fig. 2). Nano-BG appeared as 3	
spherical particles within large agglomerates, while Schott- and Mo-Sci-BG particles showed a shard-4	
like appearance with larger primary particle sizes and sharp edges. The primary particle size of nano-5	
BG was approximately 40 nm (Fig. S9) with agglomerates of 11.85 ± 6.10 µm. Schott- and Mo-Sci-6	
BG particles did not seem agglomerated and had a primary particle size of 3.27 ± 1.79 µm and 7	
10.83 ± 4.08 µm, respectively. Schott-BG showed a lean particle size distribution (Fig. S2), while Mo-8	
Sci-BG also consisted of larger single particles of up to 65 µm (Fig. 2c and S3). 9	
 10	
3.2 Morphology of nano- and microcomposites 11	
SEM images confirmed the presence of BG particles on the surface of silicone composite films 12	
(Fig. S10a-c). The large agglomerates of the nano-BG seemed to be broken up into smaller fractions. 13	
Especially the very large and shard-like Mo-Sci-particles could be observed. Cross-sectional SEM-14	
images confirmed the evenly dispersed BG particles in the silicone composite films (Fig. 3 and S8). 15	
Agglomerates of nano-BG particles were still present as seen in Fig. 3, while also smaller, more 16	
evenly dispersed nano-BG particles could be observed. Schott-BG and Mo-Sci-BG containing films 17	
seemed to have an even dispersion of incorporated particles. More detailed cross-sectional SEM 18	
images are available in the supporting information in Fig. S8. 19	
 20	
3.3 In vitro bioactivity study  21	
BG containing composites exhibited HAp formation on their surfaces (Fig. 3e-g, Fig. 4c, d, Fig. S8c, 22	
e, g). Schott-BG and Mo-Sci-BG containing films showed crater formation after four weeks in SBF, 23	
while HAp formed evenly on the surfaces of nano-BG containing films. Cross-sectional SEM images 24	
of the films showed that in nano-BG containing composites HAp was formed more evenly dispersed 25	
as compared to microcomposites. For Schott-BG and Mo-Sci-BG containing silicones, the HAp 26	
formation was located at the larger microparticles, which, due to their size, were not as well distributed 27	
across the silicone matrix as compared to the nanoparticles.  28	
12	
	
 1	
XRD patterns of as-prepared composites revealed the amorphous nature of pure and BG containing 2	
silicone films (Fig. 4c-d and Fig. S4-6). After immersion in SBF for four weeks, the characteristic 3	
signals of HAp at 2Θ = 26° (0002) and 2Θ = 31.5° (112) appeared. All diffractograms of BG 4	
containing films showed patterns for HAp and calcium carbonate (calcite) after immersion in SBF. 5	
The signals of the HAp for nano-BG containing composites were sharper compared to the 6	
microparticles containing silicone composites. The area below the HAp-signals increased with 7	
increasing particle concentrations in the films and with increasing duration of immersion. Also, 8	
depending on the particle type, the integral of the HAp peaks (specifically 112) decreased from nano-9	
BG to Mo-Sci-BG to Schott-BG, indicating the amount of measured HAp. 10	
The water uptake increased with increasing particle concentration (Fig. 4a). It was the lowest for nano-11	
BG and the highest for Mo-Sci-BG containing silicone films. For larger concentrations, the water 12	
uptake seemed to plateau and did not change significantly (p = 1) between 10 wt.% and 15 wt.% 13	
Schott-BG and Mo-Sci-BG, respectively. Pure silicone films did not show any swelling behaviour. 14	
There was no significant difference in mass loss between pure and nano-BG containing films 15	
(p = 0.68 for blank vs. 5 wt.% nano-BG, p = 0.82 for 10 wt.% nano-BG, Fig. 4b). In contrary, the 16	
weight of the films containing larger Schott-BG and Mo-Sci-BG particles were significantly larger 17	
compared to the blank (p ≤  2.27*10-7). These weight gains increased with increasing particle 18	
concentrations and plateaued for Schott-BG composites at large concentrations (p = 1 for 10 wt.% 19	
Schott-BG vs. 15 wt.% Schott-BG), while it decreased for Mo-Sci-BG composites at 15 wt.% 20	
compared to 10 wt.% Mo-Sci-BG composites (p = 2*10-7). 21	
 22	
3.4 Mechanical properties 23	
3.4.1 Static contact angle 24	
Pure silicone films showed the highest hydrophobicity and the static contact angle decreased with 25	
increasing particle concentration in the composite (Table 2). No significant difference between the 26	
materials were measured in this experiment (p ≥  0.28). 27	
 28	
13	
	
Table 2 Static contact angle [°] measurements of bioactive glass (BG) particle containing silicone 1	
films with different particle types and concentrations. The measurements were conducted in triplicates  2	
Pure Si 5% 
nano-
BG 
10% 
nano- 
BG 
5% 
Schott-
BG 
10% 
Schott-
BG 
15% 
Schott-
BG 
5%  
Mo-Sci-
BG 
10% 
Mo-Sci-
BG 
15% 
Mo-Sci-
BG 
111 ± 3 105 ± 5 107 ± 3 107 ± 1 105 ± 6 105 ± 1 108 ± 2 109 ± 3 102 ± 3 
 3	
 4	
3.4.2 Tensile strength at break 5	
The incorporation of Mo-Sci-BG microparticles decreased the tensile strength at break of the silicone 6	
films. The measurements were significant for a mass concentration of 5 wt.% (p = 0.02), while no 7	
significant results for 10 (p = 0.78) and 15 wt.% (p = 1) of Mo-Sci-BG composites could be measured 8	
compared to pure silicone, respectively. Nano-BG and Schott-BG particles did not influence the 9	
tensile strength at break of as-prepared composite films, as compared to pure silicone films (p = 1). 10	
The tensile strength at break was independent of the particle concentration (p = 1) for all particle types 11	
(Fig. 5a). After immersion in SBF for four weeks, the tensile strength at break was reduced for any 12	
type of composite film compared to as-prepared films (Fig. 5b). However, the results only showed a 13	
significant reduction of the tensile strength at break of 10 wt.% nano-BG films after immersion ins 14	
SBF compared to as-prepared films (p = 0.0005). The value for Mo-Sci-BG composites did not change 15	
significantly compared to as-prepared Mo-Sci films (p = 1), while the values of Schott-BG films after 16	
immersion in SBF reduced evenly and remained independent of the concentrations compared to as-17	
prepared films.  18	
 19	
3.4.3 Elongation at break  20	
The elongation at break of the silicone composites was reduced for composites with incorporated 21	
particles (Fig. 5c). However, a significant reduction of the elongation at break was only measured 22	
between pure silicone and 5 wt.% nano-BG (p = 0.03) and between pure silicone and 10 wt.% nano-23	
BG (p = 0.0003). The applied in vitro conditions did not have an influence on the elongation at break 24	
14	
	
of pure silicone films (p = 0.91). In contrary, the elongation at break reduced after immersion in SBF 1	
in comparison to as prepared films with increasing BG concentrations and especially for 10 wt.% 2	
nano-BG containing films with 47 ± 31%. Besides a significant reduction of elongation at break of 3	
nano-BG containing films (5 wt.% nano-BG: p = 0.00007 and 10 wt.% nano-BG: p = 0.000002) after 4	
immersion in SBF, the reduction was most distinct for films containing large BG concentrations of 5	
15 wt.%, with a significant reduction of the elongation at break of the 15 wt.% Mo-Sci-BG composite 6	
(p = 0.001) compared to the as prepared film.  7	
 8	
3.4.4 Stiffness 9	
The Young’s modulus of particle containing composites before immersion in SBF increased with 10	
increasing particle concentrations, while it decreased with increasing particle size (Fig. 5e). 11	
Specifically nano-BG containing composites were stiffer with increasing particle composition 12	
(p < 2*10-22), but also Schott-BG composites and Mo-Sci-BG composites were stiffer with increasing 13	
particle composition compared to pure silicone. There was no significant difference between Schott-14	
BG and Mo-Sci-BG containing composites at the same compositions (5 wt.%: p = 0.09 ; 10 wt.%: 15	
p = 0.50; 15 wt.%: p = 0.42). After immersion in SBF, the Young’s modulus increased significantly 16	
for all particle-loaded samples compared to the value of the as-prepared composites (p < 0.002).  The 17	
stiffness of pure silicone films did not change significantly after immersion in SBF (p = 0.33, Fig. 5f). 18	
5 wt.% nano-BG increased by a factor of two, while 10 wt.% nano-BG increased by a factor of five. 19	
No systematic trend was found regarding a difference of Schott- and Mo-Sci-BG.  20	
 21	
3.5 Cell culture study 22	
Cell viability of primary human dermal fibroblasts did not differ significantly on BG containing 23	
silicone than on pure silicone after 24 hours (p = 1, Fig. 6). After three days, the viabilities of the cells 24	
on 5 wt.% (p = 0.02) and 10 wt.% (p = 0.0004) Schott-BG and 10 wt.% Mo-Sci-BG (p = 0.04) were 25	
significantly larger than on pure silicone on day 3. On day 3, only the viability on 10 wt.% Schott-BG 26	
was significantly larger compared to other BG containing silicones (5 wt.% nano-BG: p = 7.3*10-4 and 27	
10 wt.% nano-BG: p = 0.02). After seven days, the viability of the cells on all BG-loaded silicones 28	
15	
	
(p ≤  2.8*10-6), except 5 wt.% nano-BG (p = 1) was significantly larger than on pure silicone on day 7. 1	
The viability on pure silicone did neither increase from day 1 to day 3 (p = 1), nor from day 3 to day 7 2	
(p = 0.11). In general, the cell viability of human primary dermal fibroblasts was the largest on Schott-3	
BG containing silicones, while it was larger on Mo-Sci-BG than on nano-BG silicone composites.   4	
16	
	
4 Discussion 1	
The here presented study examined the effect of different BG45S5® types (nano-BG, Schott-BG and 2	
Mo-Sci-BG) on medical grade silicone elastomers for the use at the driveline exit sites of left 3	
ventricular assist devices. As this position is specifically susceptible for infection, a stable polymer-4	
skin interface is highly desirable, thus giving a barrier against pathogens [24]. Bioactive glass was 5	
chosen in this study, because of its reported wound healing properties and ability to improve the 6	
bioactivity of polymers [8,12,22,35]. The experiments explored, whether the simple incorporation of 7	
BG into silicone elastomers influences mechanical properties, improves bioactivity of silicone in body 8	
fluids and improves the silicone’s cytocompatibility with human dermal cells. The use of different 9	
bioactive glasses enabled to study the influence of the particle size on the examined properties.  10	
Incorporation of BG particles into silicone elastomers allowed the modification of mechanical and 11	
cytocompatibility properties of the polymer by pure mechanical mixing in an efficient way without the 12	
need for additional solvents or additives during production. Immersion of the silicone composites in 13	
simulated body fluid proved the HAp forming ability of the materials and thus its bioactivity. 14	
Improved cytocompatibility of primary human dermal fibroblasts with BG-filled silicone was proven. 15	
In the context of left ventricular assist device drivelines, the materials are suitable to cover the skin-16	
penetrating driveline at the driveline exit site, improving the bioactivity and cytocompatibility 17	
compared to pure silicone. 18	
 19	
4.1 Manufacturing  20	
The manufacturing process was based on simple mechanical mixing and yielded well-distributed 21	
particles within the silicone matrix (Fig. 3). However, in contrast to the Schott-BG and Mo-Sci-BG 22	
microparticles the production of films incorporating nano-BG particles at concentrations larger than 23	
10 wt.% was not possible, even at increased curing temperatures. The large surface area of nano-BG 24	
compared to the microparticles may result in large agglomerate formation, causing phase separation of 25	
the filler and the silicone and finally inhibiting the curing reaction due to the resulting large viscosity. 26	
Another explanation could be the inhibition of the platinum catalyst of the silicone elastomer caused 27	
17	
	
by the nanoparticles. This has been reported earlier by Fahrni et al. (2009) in a mixture of iron oxide 1	
nanoparticles in poly(dimethylsiloxane) [36]. Schrooten et al. (2004) already reported the use of a BG 2	
coating with silicone rubber for percutaneous implants [37]. They used electron beam ablation to coat 3	
poly(dimethylsiloxane) with bioactive glass. However, the pure mechanical mixing reported here 4	
seems simpler and less technically demanding. As the particles can also be chemically defined prior to 5	
mixing into the uncured silicone, it is also possible to produce a more well-defined material, compared 6	
to the in situ formation of the BG with electron beam ablation. 7	
 8	
4.2 Bioactivity  9	
The in vitro study in SBF proved the formation of HAp and, thus, the bioactivity of BG containing 10	
silicone composites. The formation of HAp was confirmed visually by SEM (Fig. 3, Fig. S8), as well 11	
as by its crystal structure observed on XRD patterns with the characteristic signals at 2Θ = 26° (0002) 12	
and 2Θ = 31.5° (112) (Fig. 4c-d, Fig. S4-6). More HAp precipitated on nano-BG than on Schott-BG or 13	
Mo-Sci-BG containing silicone materials. This increased potential of nano-BG particles to form HAp 14	
was already reported earlier by Mačković et al. (2012) and is attributed to the high surface reactivity of 15	
the nanoscale particles [38]. Mačković et al. (2012) also reported the formation of nanocrystalline 16	
HAp on nano-BG compared to BG microparticles. This could not be observed here as the peaks of 17	
HAp, formed on all BG containing composites seemed evenly broad, thus allowing no statements 18	
regarding HAp crystallite size. The formation of calcite on SBF-immersed Bioglass was already 19	
reported in earlier studies and is attributed to the mechanism of HAp formation in SBF [39,40]. Larger 20	
surface areas of BG favour the release of calcium from BG, which increases the ratio of the calcium to 21	
phosphorous ions in solution (Ca/P ratio) [39,40]. This causes the precipitation of calcite at the 22	
expense of HAp formation, which takes place in parallel in the first stages of BG reactions in SBF 23	
[38,39]. Swelling of the composites in SBF was more prolonged for microparticles containing 24	
silicones than for nanocomposites. It suggests a reduced shape stability of the possibly implanted 25	
devices in the body, when microparticles are used. 26	
 27	
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4.3 Cytocompatibility 1	
Human primary dermal fibroblasts were chosen for this study. Besides keratinocytes and dermal 2	
microvascular endothelial cells, they serve as a standard cell culture model to evaluate the interface 3	
between skin and percutaneous devices [41]. As the goal of this study was to gain a first evaluation, 4	
whether BG could serve as a material to improve the cytocompatibility at the skin of silicone 5	
elastomers, the study confined itself to the measurement of the fibroblast cell proliferation and the 6	
influence of different BG silicone composites thereof. The results showed that BG containing silicone 7	
seems to allow a faster cell proliferation of human dermal fibroblasts than pure medical grade silicone. 8	
The slow proliferation of cells on pure silicone is attributed to the silicone elastomers’ inertness and, 9	
thus, weak protein (Fig. S11) and cell attachment, which leads to weak soft tissue integration [42,43]. 10	
The incorporation of BG into the silicone seems to allow a faster cell attachment of human dermal 11	
fibroblasts, which is a requirement for the proliferation of this cell type. This faster proliferation of the 12	
skin cells on the BG silicone composites could allow faster wound closure between the implant and 13	
skin, thus forming a silicone-skin interface and a barrier against pathogens [22]. Once the dermal cells 14	
are able to proliferate on the polymer, faster skin biointegration of percutaneous materials is most 15	
likely. Also, the abilities of BG to support rapid wound closure has been shown earlier by Cai et al. 16	
(2012), who incorporated BG in an ointment and applied it to full thickness skin wounds in a rabbit 17	
model. They observed significantly shorter healing times with BG containing ointments compared to 18	
the control [35]. The combination of improved cell proliferation and reduced healing times makes BG 19	
a suitable material to improve the cytocompatibility of pure silicone and might therefore form an 20	
improved silicone-skin interface. However, the use of such BG containing silicones should not be 21	
considered for the use in other silicone elastomer containing implants, such as e.g. breast implants. 22	
Here, silicone shell incrustation (calcification) is problematic, leading to stiffening and, in most 23	
dramatic cases implant rupture [44]. The use of BG containing silicones with LVADs, would need to 24	
be limited to the driveline exit site. The measured cell viability and proliferation on BG containing 25	
silicones is limited compared to the surfaces of well plates and cell flasks but the comparison to pure 26	
medical grade silicone is promising. In addition, the increased cell viability on BG containing silicones 27	
after seven days is indicative that this material allows the formation of a possibly stable connection to 28	
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dermal cells. In general, the results allow to make an argument about the dependence of particle 1	
concentration of the silicone composite on the cell viability of the human dermal fibroblasts, which 2	
increases with particle concentration. Also microcomposites seem to promote cell proliferation better 3	
than nanocomposites. The reduced cell viability on the nano-BG containing silicones compared to 4	
Schott- and Mo-Sci-BG composites may be attributed to the increased alkalinity, induced by the 5	
dissolution of the BG particles [45].  As nano-BG exhibits larger specific surfaces and it increases the 6	
pH more than microparticles. The same applies to the viability on day 1. Due to the reaction of the BG 7	
with the cell medium, the alkalinity increased in the medium, which supposes a negative impact on the 8	
cell proliferation of fibroblasts. Still, also incorporated nano-BG increased the cell viability of cells 9	
compared to pure silicone and improved the cytocompatible properties thereof.  10	
 11	
4.4 Mechanical properties  12	
With exceptions, the results of the evaluation of the tensile strength at break and the percent 13	
elongation at break did not have statistical significance. The test method employed considers the 14	
tensile properties of thin plastic sheeting with a thickness of less than 1 mm. The test method also 15	
regards thin sheeting of elastomeric plastics with a percent elongation of larger than 100%, which 16	
justifies the choice of the test method. Despite the lack of significant results, the data still show 17	
general trends. Results were compared with the standard theories of ultimate strength and ultimate 18	
strain of particle-loaded polymer composites and tensile properties of human skin [46]. The latter is 19	
mainly defined by the properties of collagen, whose maximum strain is between 10-20%, while its 20	
maximum strength is approximately 70-150 MPa [47]. The tested silicone composites have larger 21	
values of ultimate strain, while the tensile strength at break is smaller than the one of collagen. The 22	
Young’s modulus of the skin is between 0.42 MPa for young and 0.85 MPa for older humans [48]. 23	
Thus, the composites generally show larger elastic moduli, but smaller ultimate strength compared to 24	
human skin, when possibly implanted into the body. Under large forces, caused by possible accidents 25	
of the patient, the silicon-skin interface or the material could be compromised, depending on the 26	
strength of an eventually formed silicone-skin interface.  27	
 28	
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4.4.1 Ultimate mechanical properties 1	
The tensile strength at break and percent elongation at break (other than the Young’s modulus, which 2	
is measured for small strains) depend on the weakest path throughout the structure, as opposed to the 3	
statistically averaged values of the microstructure parameters [46]. Thus, the tensile strength at break 4	
and percent elongation at break are also defined by the size of the largest particles or largest 5	
discontinuity in the films, which defines the weakest point of the film (Fig. 7). The stress-transfer 6	
under large strain is specifically weak at these positions, thus compromising the mechanical stability 7	
of the entire construct. The incorporation of particles generally decreased the ultimate tensile 8	
properties of the composites, which suggests weak particle-matrix interactions [49]. Before immersion 9	
in SBF nano-BG and Schott-BG are well incorporated into the silicone, showing some particle/matrix 10	
interaction (Fig. 3b and c), while in the Mo-Sci-BG films, voids between silicone and particles can be 11	
observed (Fig. 3d). The stress transfer between the silicone and Mo-Sci particles is weak, thus, leading 12	
to the reduced ultimate tensile properties of Mo-Sci-BG silicone composites. As the rather large Mo-13	
Sci particles also possess sharp edges due to their shard-like nature, it is possible that these edges cut 14	
the silicone under stress and caused a rupture of the film. For the smaller particles of nano-BG and 15	
Schott-BG the tensile strength at break is not influenced, even though the Schott-BG particles also 16	
show a shard-like morphology (Fig. 2b). This suggests, that the stress transfer between particles and 17	
matrix is better for smaller particles [50]. The heavily decreased ultimate properties of the nano-BG 18	
composites compared to microparticles incorporating composites after immersion in SBF are probably 19	
due to the porosity of the nano-BG agglomerates, which are, besides much smaller aggregates, present 20	
in the matrix (Fig. 3b and Fig. S8b). This porosity yields a much larger specific surface area of the 21	
nano-BG compared to non-porous particles such as Schott-BG and Mo-Sci-BG and, thus, the nano-BG 22	
agglomerates have the aforementioned higher potential to form HAp [38]. This increased formation of 23	
HAp of the nano-BG particles in the silicone was also verified by XRD (Fig. 4). HAp formed on the 24	
internal pore walls of these nano-BG agglomerates causing an internal force within the agglomerate 25	
and, thus, weakening of the structure. Under strain, the agglomerate cracked from the inside, resulting 26	
in a large weak spot in the material. Fig. 3e depicts one of the possible weak spots. These weaknesses 27	
could also be observed in light microscopy images (Fig. S7b) of the nano-BG silicone films after 28	
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immersion in SBF. As the ultimate mechanical properties are defined by the weakest path in the 1	
polymer, the weaknesses resulted in the destabilization of the entire film. Immersion in SBF also 2	
reduced the tensile strength at break of the Schott-BG containing composites, which can be explained 3	
by the reduced particle/matrix interactions caused by the formation of HAp on the surface of the 4	
particles. The reduced interactions resulted in voids between particles and silicone as seen in the cross-5	
sectional SEM images (Fig. 3f), thus weakening the stress transfer under strain. Percent elongation at 6	
break was highly affected by the immersion in SBF for all particle types. This is due to the weak force 7	
transfer between particles and matrix after immersion in SBF, yielding the maximum stress of the 8	
composite at smaller strains.  9	
 10	
4.4.2 Young’s modulus 11	
The incorporation of particles into a polymer causes a stiffening of the matrix because of the larger 12	
modulus of the solid particles [46]. Chen et al. (2010) have shown this by incorporating flame spray 13	
synthesized nanosized BG particles into poly(glycerol sebacat) (PGS) [12]. The main difference to this 14	
study lies in the hydrophobicity/hydrophilicity of the polymers and, thus, the particle/polymer 15	
interfacial adhesion. PGS has a similar hydrophilicity as collagen, while silicone is highly 16	
hydrophobic [11,51,52]. The results of the BG-silicone composites follow the same trend and coincide 17	
with known literature [46]. The Young’s modulus is generally not affected by the particle/matrix 18	
interactions because for small strains, there is insufficient dilation to cause interface separation [46]. 19	
Stiffness of silicone increased with addition of BG, indicating that no particle-matrix debonding 20	
occurred when samples were subject to tensile loading. The exaltation of the Young’s modulus with 21	
increasing particle loading can be explained by the higher modulus of the particles compared to the 22	
silicone rubber. As a first approximation of this correlation of modulus and filler volume fraction, the 23	
equation of Guth can be used [53].  24	 𝐸! 𝐸! = 1 + 2.5𝑉! + 14.1𝑉!! 
Ec and Em are the Young’s moduli of the composite and the matrix (pure silicone in this study), 25	
respectively. Vp is the particle volume fraction. Many other and more advanced equations for the 26	
description of the Young’s modulus in relation to the volume fraction of the filler exist [46]. As 27	
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indicated by the equation, higher volume fractions of inorganic fillers in the polymer result in a stiffer 1	
composite [46]. This is most probably also the explanation for the increased modulus of BG-silicone 2	
composites after immersion in SBF compared to the as-prepared films. As seen in the cross-sectional 3	
images of Fig. 3 and the light microscopy images of Fig. S7, the size of the incorporated BG particles 4	
is larger, which leads to an increase in volume fraction and, thus, causes the increased stiffness of the 5	
composites [46]. At same particle concentrations, the Young’s modulus of Schott- and Mo-Sci-BG 6	
differ only slightly, while it is significantly higher for nano-BG (p < 0.0005). This increase in Young’s 7	
modulus of nano-BG containing polymers compared to microparticles containing polymers was 8	
already reported earlier by Misra et al. (2008) and is attributed to the true reinforcement achieved 9	
using nano-BG [45]. The finer dispersed nanoparticles form crystalline HAp throughout the silicone 10	
matrix, thus causing the stiffening of the composite, while on the microparticles HAp only formers 11	
very localized at the particles. 12	
 13	
4.5 Limitations of the study 14	
The study is limited in several aspects. It cannot definitely predict, whether BG containing silicone are 15	
improving the driveline exit site of LVAD drivelines. Cell proliferation measurements of human skin 16	
cells (primary dermal fibroblasts) were conducted to assess the cytocompatibility of the material, but 17	
do not allow predictions about cell adhesion and long-term skin tissue integration. Mechanical testing 18	
showed results with large standard deviations. Some trends are visible, though mainly without 19	
statistical significance. Moreover, at increased sample sizes, it is improbable, that standard deviations 20	
decrease, as this was tested for 5 wt.% Mo-Sci-BG containing silicone with a samples size of 14. 21	
However, specifically the incorporation of nanosized particles is difficult at the presented 22	
concentrations. The static contact angle measurements also showed large errors and no significant 23	
results and trends could be observed. Still, as for the mechanical testing, some minor trends are visible 24	
and increased sample sizes could improve the results. 25	
26	
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5 Conclusion 1	
Incorporation of nano-BG particles into silicone composites showed the highest bioactivity as 2	
measured by XRD and least swelling by 50%, but lower mechanical properties with an ultimate tensile 3	
strength of only 2 MPa after simulation of the environment in the human body and lower 4	
cytocompatibility. In contrast, micron sized particles were twice more cytocompatible than 5	
nanoparticles and had better mechanical properties and easier handling. Choosing the “right” particle 6	
type constitutes as a trade-off between different properties and will depend on the specific use. In the 7	
case of driveline material for LVAD implantation the use of nanosized BG45S5® would be more 8	
advantageous because of higher bioactivity and less swelling inside the body. In conclusion, this study 9	
served as a first evaluation, if BG containing silicone elastomers could be a suitable material for 10	
LVAD drivelines. The here presented mechanical properties and cytocompatibility are promising. 11	
Whether the materials meet the conditions for long-term implantation as a percutaneous driveline, 12	
especially with a focus on mechanical integrity, skin biointegration and reduced infection rates, has to 13	
be assessed in an animal model with the final LVAD driveline shape.   14	
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Figure captions 23	
Fig. 1 Sketch of the surgical technique of implanting the driveline of a left ventricular assist device. In 24	
(a) the velour is placed at the driveline exit site yielding a velour-skin interface. (b) shows an 25	
implanted driveline with a polymer-skin interface at the driveline exit site. In this case, the velour 26	
30	
	
portion of the driveline is completely internalized inside the patient’s body. With the courtesy of 1	
Berlin Heart GmbH  2	
 3	
Fig. 2 Scanning electron microscopy images of the different bioactive glass BG45S5® particles. (a) 4	
nanosized bioactive glass (nano-BG), prepared by flame spray synthesis, commercial microparticles 5	
by (b) Schott (Schott-BG) and (c) Mo-Sci Corporation (Mo-Sci-BG) 6	
 7	
Fig. 3 Cross-sectional scanning electron microscopy images of as-prepared silicones containing 8	
10 wt.% bioactive glass (BG45S5®) particles. (a) the pure silicone, (b) with nanosized bioactive glass 9	
(nano-BG), (c) with microparticles by Schott (Schott-BG) and (d) with microparticles by Mo-Sci-10	
Corporation (Mo-Sci-BG). Fig. 3e-g show the respective particle containing composite films after four 11	
weeks immersed in simulated body fluid 12	
 13	
Fig. 4 Surface and bulk composite changes after in vitro tests in simulated body fluid (SBF). (a) gives 14	
the water uptake (%WA) of the wet films after four weeks in SBF, while (b) shows the respective 15	
weight loss (%WL) of the dry films. (c) X-ray diffractogram (XRD) of a nano-BG containing silicone 16	
film after four weeks in SBF and its concentration dependence; (d) illustrates the respective 17	
dependence of the particle type at a constant concentration of 10 wt.% (* 15 wt.% composition of 18	
nano-BG was not producible) 19	
 20	
Fig. 5 The influence of different bioactive glass (BG45S5®) particles and particle concentrations in 21	
silicone films on the mechanical properties of the composite. (a) gives the tensile strength at break of 22	
the as-prepared silicone films as a function of concentration and particle type, while (b) gives the 23	
respective values, after immersion in simulated body fluid (SBF). (c) shows the percent elongation at 24	
break of the as-prepared films and (d) depicts the value after immersion in SBF for four weeks. (e) and 25	
(f) represent the Young’s modulus of the films before and after immersion in SBF (* 15 wt.% 26	
composition of nano-BG was not producible) (e) also contains typical stress-strain curves of as 27	
31	
	
prepared films with a weight fraction of particles of 5 wt.%. The number of samples for the 1	
measurements of as-prepared materials was n ≥  4, while the number of samples for materials, which 2	
had been immersed in SBF was n ≥  3 3	
 4	
Fig. 6 Cell proliferation of human primary dermal fibroblasts on different bioactive glass (BG45S5®) 5	
containing silicone composites. It shows the dependence of the cell viability on the particle type 6	
(nano-BG, Schott-BG and Mo-Sci-BG). The cell viabilities are compared to the one of day 1 on pure 7	
silicone. Positive control data are not shown, as it exceeded the viability of the best performing 8	
material by approximately 4-fold (*: significant differences for p < 0.05) 9	
 10	
Fig. 7 Tensile strength at break (a), the percent elongation at break (b) and Young’s modulus (c) of 11	
silicone films depending on the size of the largest particles or agglomerates, which are incorporated in 12	
silicone. In this analysis the mean particle diameter of the three largest particles at the position of 13	
rupture were analysed. The films that include particles at a concentration of 10 wt.% before and after 14	
immersion in simulated body fluid for four weeks and pure silicone were considered 15	
 16	
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Materials and methods 
Light microscopy analysis of the composite films 
Particle sizes in the films were investigated by light microscopy (Zeiss Axio Imager.M2m, 100x 
magnification, bright field mode, Carl Zeiss AG, Feldbach, Switzerland). Rectangles of 5 x 5 mm 
were cut at the position of rupture of the tested films with a particle concentration of 10 wt.%. These 
rectangles were washed with ethanol and gently wiped in order to remove possible dirt or loosely 
attached particles on the surface. Subsequently, the samples were dried and examined. The area with 
the largest particles in this rectangle was chosen and the size of the particles measured using an ellipse 
as described above. The diameters of the 50 largest particles in the area were considered. Every 
composite material was measured in triplicates. 
 
Protein adsorption assay (PAA) 
A protein adsorption assay was adapted from Wei et al. [1]. A stock solution of 1.25% Fetal Bovine 
Serum (FBS, gibco®, Paisley, United Kingdom) in phosphate buffered saline (PBS, PBS pH 7.4 (1X), 
gibco®) was prepared and stored at 8 °C. Samples of the different materials with a diameter of 10 mm 
were punched and placed in a 1.5 mL Eppendorf tube. 1 mL of ethanol was added and shaken at 
1050 rpm for 30 minutes in a thermomixer (ThermoMixer F1.5, Vardaux-Eppendorf AG, Basel, 
Switzerland) at room temperature. After removal of the ethanol, 1 mL of pure PBS was added and the 
samples were shaken for 24 hours at 1050 rpm. Subsequently, PBS was removed and replaced by 
0.5 mL of 1.25% FBS in PBS and incubated at 37 °C. Protein adsorption was analysed using a 
commercially available Protein Assay Kit (PierceTM BCA Protein Assay Kit, Thermo Scientific, 
Rockford IL, United States). Every composite and every sample tube was tested in triplicates.  
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Results 
Particle size distributions 
 
Fig. S1 Agglomerate size distribution (PSD) of the nano-particulate Bioglass 45S5®, which was 
produced by flame-spray synthesis. The PSD was fitted using a non-weighted non-linear Lorentz-fit 
 
 
Fig. S2 Particle Size Distribution (PSD) of the primary particles of Bioglass 45S5® provided by 
Schott (Schott-BG). The PSD was fitted using a non-weighted non-linear Lorentz-fit 
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Fig. S3 Particle Size Distribution (PSD) of the primary particles of Bioglass 45S5® provided by mo-
Science (Mo-Sci-BG). The PSD was fitted using a non-weighted non-linear Lorentz-fit 
 
X-ray diffractogram 
 
Fig. S4 X-ray diffractogram of Bioglass BG 45S5® containing silicone elastomer as a function for 
different immersion times in simulated body fluid. The bioactive glass was produced by flame spray 
synthesis 
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Fig. S5 X-ray diffractogram of bioactive glass (BG 45S5®) supplied by Schott (Schott-BG) in silicone 
elastomer at different weight percentages after immersion in simulated body fluid for four weeks 
 
 
 
Fig. S6 X-ray diffractogram of bioactive glass (BG 45S5®) supplied by mo-Science Inc. (Mo-Sci-BG) 
in silicone elastomer at different weight percentages after immersion in simulated body fluid for four 
weeks 
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Light microscopy 
 
Fig. S7 Light microscopic images of the Bioglass (BG45S5®) containing silicone composites before 
(a, c and e) and after (b, d and f) immersion in simulated body fluid. (a) and (b) show the nanosized 
BG, (c) and (d) show micronized BG by Schott (Schott-BG) and (e) and (f) give micronsized BG by 
mo-Science (Mo-Sci-BG) 
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Scanning electron microscopy 
 
Fig. S8 Detailed cross-sectional scanning electron microscopy images of as-prepared silicones 
containing 10 wt.% bioactive glass (BG45S5®) particles. (a) of pure silicone, (b) with nanosized 
bioactive glass (nano-BG), (d) with microparticles by Schott (Schott-BG) and (f) with microparticles 
by mo-Sci-Corporation (Mo-Sci-BG). Fig. 2c, 2e and 2g show the respective composite films after 
four weeks immersed in simulated body fluid 
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Fig. S9 Scanning electron microscopy images of the agglomerated primary particles of nanosized 
bioactive glass (nano-BG) of the type BG 45S5® produced by flame spray synthesis 
 
 
Fig. S10 Planar section scanning electron microscopy images of as-prepared silicones containing 
10 wt.% bioactive glass (BG45S5®) particles. (a) with nanosized bioactive glass (nano-BG), (b) with 
microparticles by Schott (Schott-BG) and (c) with microparticles by mo-Sci-Corporation (Mo-Sci-
BG). Fig. S10d-f show the respective composite films after four weeks immersed in simulated body 
fluid 
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Protein adsorption assay  
 
Fig. S11 Protein adsorption study on different bioactive glass containing silicone composites as a 
function of particle mass concentration and particle type (*: 15 wt.% composition of nano-BG was not 
producible) 
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